| Drug ID: | Drug94 |
|---|---|
| Drug Name: | Morphine |
| CID: | 5288826 |
| DrugBank ID: | DB00295 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT01477190 |
| Molecular Formula: | C17H19NO3 |
| Molecular Weight: | 285.34 g/mol |
| Isomeric SMILES: | CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O |
| Synonyms: | morphine; Morphia; Morphium; Morphin; Morphinum; (-)-Morphine; Morphina; Ospalivina; Duromorph; 57-27-2 |
| Phase 0: | 21 |
| Phase 1: | 79 |
| Phase 2: | 178 |
| Phase 3: | 196 |
| Phase 4: | 371 |
| Description: | The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt791 | 5288826 | Morphine | 25601 | Oprm1 | Rattus norvegicus (Norway rat) | 8114680 | Partial agonist |
| dt792 | 5288826 | Morphine | 4988 | OPRM1 | Homo sapiens (human) | Full agonist | |
| dt793 | 5288826 | Morphine | 29335 | Oprk1 | Rattus norvegicus (Norway rat) | Partial agonist | |
| dt794 | 5288826 | Morphine | 4986 | OPRK1 | Homo sapiens (human) | 9686407 | Partial agonist |
| dt795 | 5288826 | Morphine | 4985 | OPRD1 | Homo sapiens (human) | 9686407 | Full agonist |
| dt796 | 5288826 | Morphine | 4988 | OPRM1 | Homo sapiens (human) | Agonist|Regulator | |
| dt797 | 5288826 | Morphine | 4986 | OPRK1 | Homo sapiens (human) | Agonist | |
| dt798 | 5288826 | Morphine | 4985 | OPRD1 | Homo sapiens (human) | Agonist | |
| dt799 | 5288826 | Morphine | 23643 | LY96 | Homo sapiens (human) | 20178837 | Activator |
| dt800 | 5288826 | Morphine | 1558 | CYP2C8 | Homo sapiens (human) | Substrate |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00982618 | Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine | None | COMPLETED | McGill University Health Centre/Research Institute of the McGill University Health Centre | Colon Cancer; Inflammatory Bowel Diseases; Divert… | DRUG: Lidocaine; PROCEDURE: Epidural Block; DRUG:… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine…
PMID: 31248978
Year: 2019
Relationship Type:
Treatment
Score: 10.0
Opioids are highly effective analgesics, however, their therapeutic use is limited by adverse effects that include respiratory depression, dependence…
Immunomodulatory effects of fentanyl and morphine on DSS- and TNBS-induced coli…
PMID: 35848944
Year: 2022
Relationship Type:
Mechanism
Score: 9.5
BACKGROUND: Opioid prescription for inflammatory bowel disease (IBD)-related pain is on the rise. However, the use of strong opioids can result in se…
Morphine Exacerbates Experimental Colitis-Induced Depression of Nesting in Mice
PMID: 35295474
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physi…